Charpentier collects CRISPR/Cas9 tech patents for gene editing in Japan and US
ERS Genomics says its patent applications have been approved in the US and Japan, and the pace of license deals has increased to up to four per month.
ERS Genomics says its patent applications have been approved in the US and Japan, and the pace of license deals has increased to up to four per month.
Tot Biopharm has opened its second monoclonal antibody (mAb) production plant in Suzhou Industrial Park, China.
CellGenix has added quality control and R&D laboratories as well as logistics and warehouse space to its headquarters in Freiburg, Germany.